Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,296 papers from all fields of science
Search
Sign In
Create Free Account
Lymphoma, Intermediate-Grade
Known as:
Intermediate-Grade Lymphomas
, Lymphoma, Intermediate Grade
, Lymphomas, Intermediate-Grade
Expand
A type of lymphoma that grows and spreads quickly and has severe symptoms. Also called aggressive lymphoma and high-grade lymphoma.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Lymphoma, Non-Hodgkin
Neoplastic Cell
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
Deletion of 6q27 in chronic lymphocytic leukemia and multiple myeloma detected by fluorescence in situ hybridization.
A. Amiel
,
I. Mulchanov
,
+4 authors
M. Lishner
Cancer Genetics and Cytogenetics
1999
Corpus ID: 45795915
1998
1998
Apoptosis-associated proteins in oral lymphomas from HIV-positive patients.
J. Regezi
,
A. Mcmillan
,
+4 authors
B. Ziober
Oral surgery, oral medicine, oral pathology, oral…
1998
Corpus ID: 26897229
1995
1995
Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
A. Younes
,
A. Sarris
,
+7 authors
L. North
Journal of Clinical Oncology
1995
Corpus ID: 43244722
PURPOSE Paclitaxel (Taxol; Bristol-Myers Squibb Co, Princeton, NJ) is a novel antimicrotubule agent with anti-tumor activity…
Expand
Review
1995
Review
1995
T-cell-rich B-cell lymphoma. A clinicopathologic study of eight cases.
F. Baddoura
,
W. Chan
,
A. Masih
,
D. Mitchell
,
N. Sun
,
D. Weisenburger
American Journal of Clinical Pathology
1995
Corpus ID: 38246249
Although T-cell-rich B-cell lymphoma (TCRBCL) is a recently recognized form of non-Hodgkin's lymphoma (NHL), limited information…
Expand
1994
1994
Autologous bone marrow transplantation in adults with non‐Hodgkin's lymphoma: A southwest oncology group study
R. Saez
,
S. Dahlberg
,
+4 authors
R. Fisher
Hematological Oncology
1994
Corpus ID: 26071511
Patients with non‐Hodgkin's lymphoma (NHL) who fail conventional chemotherapy have a dismal outcome. Reports from single…
Expand
Review
1994
Review
1994
Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma.
R. Pettengell
,
D. Crowther
Annals of Oncology
1994
Corpus ID: 32027665
Here we review the evidence that cytotoxic dose intensity is an important determinant of outcome in high- and intermediate-grade…
Expand
1993
1993
A comparative assessment of proliferating cell nuclear antigen, c-myc p62, and nucleolar organizer region staining in non-Hodgkin's lymphomas: a histochemical and immunohistochemical study of 200…
P. Korkolopoulou
,
E. Patsouris
,
+5 authors
C. Kittas
Human Pathology
1993
Corpus ID: 878829
1993
1993
Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group.
C. Gisselbrecht
,
É. Oksenhendler
,
+7 authors
M. Raphael
American Journal of Medicine
1993
Corpus ID: 22964158
PURPOSE An increased risk of high-grade non-Hodgkin's lymphoma is observed in patients who are seropositive for human…
Expand
Review
1991
Review
1991
The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma.
R. Meyer
,
W. Hryniuk
,
M. Goodyear
Journal of Clinical Oncology
1991
Corpus ID: 25196523
To determine whether the dose intensity of chemotherapeutic regimens correlates with the complete remission rate in adult…
Expand
Highly Cited
1990
Highly Cited
1990
The Value of Immunophenotyping on Paraffin Sections in the Identification of T‐Cell Rich B‐Cell Large‐Cell Lymphomas: Lineage Confirmed by JH Rearrangement
B. Osborne
,
J. Butler
,
W. Pugh
American Journal of Surgical Pathology
1990
Corpus ID: 8036024
Immunophenotyping of lymphomas using paraffinembedded lymphoid tissue, not previously distorted by frozen section, is useful in…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE